Synovial Sarcoma Market Pipeline Landscape Report 2022: Comprehensive Insights on 14+ Companies and 14+ Pipeline Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Synovial Sarcoma- Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.

This Synovial-Sarcoma- Pipeline Insight, 2022 report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Synovial-Sarcoma pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Synovial-Sarcoma- Pipeline Insight, 2022 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Synovial-Sarcoma pipeline landscape is provided which includes the disease overview and Synovial-Sarcoma treatment guidelines.

The assessment part of the report embraces, in depth Synovial-Sarcoma commercial assessment and clinical assessment of the pipeline products under development.

In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Synovial-Sarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Synovial-Sarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Synovial-Sarcoma.

Synovial-Sarcoma Emerging Drugs Chapters

This segment of the Synovial-Sarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Synovial-Sarcoma Emerging Drugs

CFT 8634: C4 Therapeutics

CFT8634 is a BiDACT degrader targeting BRD9 for the treatment of cancers that are dependent on BRD9, including synovial sarcoma and SMARCB1 deleted cancers. However, C4T’s TORPEDO platform was leveraged to discover CFT8634, an orally bioavailable, selective degrader of BRD9. Unlike BRD9 inhibition, BRD9 degradation is efficacious in preclinical models of synovial sarcoma. In December 2021, the FDA cleared C4T’s investigational new drug (IND) application for CFT8634 to proceed with the proposed Phase 1/2 trial in patients with synovial sarcoma and SMARCB1-null solid tumors.

FHD 609: Foghorn Therapeutics

FHD-609, is a protein degrader of BRD9. BRD9 is a component of one form of the BAF complex. Nearly all synovial sarcoma cancers contain a translocation, a type of mutation, between a BAF subunit gene, SS18, and another set of genes. This mutation causes cancer cells to rely on BRD9 for their survival.FHD-609 has two domains: one that binds to BRD9 and the other that binds to a complex that directs proteins for destruction. By targeting BRD9 for degradation, FHD-609 depletes a key subunit of the BAF complex that is required for the survival of cancer cells. The drug is currently in Phase I stage of Clinical trial evaluation for the treatment of Synovial sarcoma.

BA-3011: BioAtla

BA3011, CAB-AXL-ADC, a conditionally and reversibly active antibody drug conjugate targeting the receptor tyrosine kinase AXL, as a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC) and ovarian cancer, with other potential indications in the future.

The Office of Orphan Drug Products (OODP) at FDA granted Orphan Drug Designation to BA3011 for the treatment of soft tissue sarcoma, and Phase I results in sarcoma patients were presented at the recent Connective Tissue Oncology Society (CTOS) 2021 Annual Meeting. BA3011 was generally well tolerated in this refractory sarcoma population. Few patients discontinued due to an adverse event (2 patients out of 26 or 7.7%). No clinically meaningful on-target toxicity to normal AXL-expressing tissue was observed.

Synovial-Sarcoma: Therapeutic Assessment

This segment of the report provides insights about the different Synovial-Sarcoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Synovial-Sarcoma

There are approx. 14+ key companies which are developing the therapies for Synovial-Sarcoma. The companies which have their Synovial-Sarcoma drug candidates in the most advanced stage, i.e. phase II include, BioAtla.

Synovial-Sarcoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Synovial-Sarcoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Synovial-Sarcoma drugs.

Key Players

• BioAtla
• C4 Therapeutics
• Foghorn Therapeutics
• OncoTherapy Science
• Adaptimmune
• Incyte Corporation
• PharmaMar

Key Players

• FHD 609
• CFT 8634
• BA-3011
• OTSA101-DTPA-111In
• afamitresgene autoleucel
• Itacitinib
• Lurbinectedin

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/j0nfp5

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900